Press coverage about MYOS RENS Technology (NASDAQ:MYOS) has trended positive this week, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MYOS RENS Technology earned a coverage optimism score of 0.35 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.402885744962 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of MYOS RENS Technology (MYOS) remained flat at $$1.25 during midday trading on Monday. The stock had a trading volume of 17,451 shares, compared to its average volume of 128,342. MYOS RENS Technology has a 1-year low of $1.03 and a 1-year high of $3.28. The company has a market cap of $7.93, a PE ratio of -1.89 and a beta of 1.49.
Separately, ValuEngine raised MYOS RENS Technology from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.
MYOS RENS Technology Inc, a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity.
Receive News & Ratings for MYOS RENS Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS RENS Technology and related companies with MarketBeat.com's FREE daily email newsletter.